Skip to content
A873 PRESURVEY - JAK/TYK2 Inhibition: New Frontiers in the Treatment of Psoriasis
PLEASE COMPLETE THIS PRESURVEY BEFORE THE START OF THE PRESENTATION
*
1.
Which of the following is a JAK-mediated cytokine active in psoriasis?
(Required.)
a. Erythropoietin (EPO)
b. IL-12
c. IL-17
d. TNF-alpha
*
2.
How confident are you that you selected the correct response for the previous question?
(Required.)
a. Not at all confident
b. Somewhat confident
c. Confident
d. Very confident
*
3.
The results of the phase 2 trial of deucravacitinib (BMS-986165) in psoriasis show which of the following?
(Required.)
a. Patients receiving deucravacitinib at least 3 mg/day achieved PASI75 and PASI90 at rates similar to those seen with biologics
b. Patients receiving deucravacitinib at least 3 mg/day achieved PASI75 and PASI90 scores that are greater than those seen with biologics
c. Patients receiving deucravacitinib at least 3 mg/day achieved PASI75 and PASI90 scores that are similar to responses seen with apremilast
d. Patients receiving deucravacitinib at least 3 mg/day achieved PASI75 and PASI90 scores at significantly greater rates than placebo but less than what is seen with biologics
*
4.
Which of the following is correct regarding the theoretical mechanistic safety of TYK2 inhibition compared with JAK inhibitors?
(Required.)
a. TYK2 inhibition potentially reduces the likelihood of viral infections
b. TYK2 inhibition potentially reduces the likelihood of bacterial infections
c. TYK2 inhibition potentially reduces the likelihood of malignancy
d. TYK2 inhibition potentially reduces the likelihood of anemia
*
5.
How confident are you that you selected the correct response for the previous question?
(Required.)
a. Not at all confident
b. Somewhat confident
c. Confident
d. Very confident
*
6.
Recent data from the POETYK-PSO-1 trial in psoriasis shows deucravacitinib was superior to placebo and which active comparator for PASI75 response at week 16?
(Required.)
a. Adalimumab
b. Apremilast
c. Etanercept
d. Ustekinumab
*
7.
Francine is a 43-year-old woman with moderate to severe plaque psoriasis with nail involvement, and psoriatic arthritis involving her peripheral joints. Which of the following is likely to be most beneficial?
(Required.)
a. Tildrakizumab
b. Guselkumab
c. Risankizumab
d. Tofacitinib
8.
Please indicate the Regional Meeting you will be attending (Select 1)
University of California Los Angeles: April 27, 2021
Oregon Dermatology Society: September 8, 2021
Pennsylvania Association of Dermatology (PAD): September 25, 2021
Pacific Regional Meeting: September 30, 2021
ODAC Webinar: October 7, 2021
Northeast Regional Meeting: October 14, 2021
Houston Dermatological Society: January 10, 2022
University of Minnesota, Department of Dermatology Grand Rounds: February 16, 2022
Regional Meeting: February 16, 2022
*
9.
Please complete the following
(Required.)
Full Name
Email
*
10.
Paradigm Medical Communications, LLC may email information about this and other continuing education activities to the email address indicated above
(Required.)
Yes
No
